Abstract
Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Current Neuropharmacology
Title: Past, Present and Future Therapeutics for Cerebellar Ataxias
Volume: 8 Issue: 1
Author(s): D. Marmolino and M. Manto
Affiliation:
Keywords: Cerebellum, ataxias, dominant, recessive, X-linked, therapy
Abstract: Cerebellar ataxias are a group of disabling neurological disorders. Patients exhibit a cerebellar syndrome and can also present with extra-cerebellar deficits, namely pigmentary retinopathy, extrapyramidal movement disorders, pyramidal signs, cortical symptoms (seizures, cognitive impairment/behavioural symptoms), and peripheral neuropathy. Recently, deficits in cognitive operations have been unraveled. Cerebellar ataxias are heterogeneous both at the phenotypic and genotypic point of view. Therapeutical trials performed during these last 4 decades have failed in most cases, in particular because drugs were not targeting a deleterious pathway, but were given to counteract putative defects in neurotransmission. The identification of the causative mutations of many hereditary ataxias, the development of relevant animal models and the recent identifications of the molecular mechanisms underlying ataxias are impacting on the development of new drugs. We provide an overview of the pharmacological treatments currently used in the clinical practice and we discuss the drugs under development.
Export Options
About this article
Cite this article as:
Marmolino D. and Manto M., Past, Present and Future Therapeutics for Cerebellar Ataxias, Current Neuropharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157015910790909476
DOI https://dx.doi.org/10.2174/157015910790909476 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Glutamate Transporter 1: Target for the Treatment of Alcohol Dependence
Current Medicinal Chemistry Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design Immune Senescence and Vaccination in the Elderly
Current Topics in Medicinal Chemistry Novel Thermosensitive Pentablock Copolymers for Sustained Delivery of Proteins in the Treatment of Posterior Segment Diseases
Protein & Peptide Letters Drug Delivery System Based on Responses to an HIV Infectious Signal
Medicinal Chemistry Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Molecular Methods for Individualization of Psychotropic Drug Treatment
Current Pharmacogenomics Healthspan and Longevity in Mammals: A Family Game for Cellular Organelles?
Current Pharmaceutical Design Molecular Determinants of Enzyme Cold Adaptation: Comparative Structural and Computational Studies of Cold- and Warm-Adapted Enzymes
Current Protein & Peptide Science REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Intra-Articular Drug Delivery: A Fast Growing Approach
Recent Patents on Drug Delivery & Formulation Naturalistic Measurement of Sleep in Older Adults with Amnestic Mild Cognitive Impairment: Anxiety Symptoms Do Not Explain Sleep Disturbance
Current Alzheimer Research Design of Iodine-Lithium-α-Dextrin Liquid Crystal with Potent Antimicrobial and Anti-Inflammatory Properties
Current Pharmaceutical Design Heavy Metal Toxicity in Humans and its Preventive and Control Measures
Current Nutrition & Food Science TGF-β in Epithelial to Mesenchymal Transition and Metastasis of Liver Carcinoma
Current Pharmaceutical Design Current Issues in the Management of Pediatric Functional Abdominal Pain
Reviews on Recent Clinical Trials Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
Current Topics in Medicinal Chemistry Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Applications of Positron Emission Tomography in Neuropsychiatric Pharmaceutical Drug Development
Current Radiopharmaceuticals Mesenchymal Stem Cells as a Source of Dopaminergic Neurons: A Potential Cell Based Therapy for Parkinson's Disease
Current Stem Cell Research & Therapy